#Biologics
Explore articles tagged with Biologics
Why API Self-Reliance Is Back at the Centre of India’s Pharma Strategy
In BW Healthcare World, HRV Pharma MD & CEO Hari Kiran Chereddi outlines why API self-reliance has re-emerged as a strategic priority under Biopharma SHAKTI and what it means for India’s pharmaceutical future.
Union Budget 2026–27: Strengthening India’s Biopharma Ecosystem and Healthcare Access
HRV Pharma CEO Hari Kiran Chereddi shares his insights on how Union Budget 2026–27’s focus on biopharma innovation, affordable cancer care, and healthcare infrastructure will shape India’s pharmaceutical future.
HRV Pharma Partners with Haleos Labs to Accelerate Orphan and Niche API Development
HRV Pharma has entered a multi‑year strategic partnership with Haleos Labs to accelerate the development and manufacture of orphan and niche APIs, strengthening global access to complex therapies for rare diseases.
How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis
HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.
HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model
Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.
Indian Biosimilars on the Global Stage: HRV Pharma CEO's Insights in Express Pharma
India's rise in biosimilars & biologics. Full clipping + insights included.